Benlysta® (belimumab) – Expanded indication
April 26, 2019 - The FDA announced the approval of GlaxoSmithKline’s Benlysta (belimumab), for the treatment of patients aged 5 years and older with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.
Download PDF
